Richard Porter

Dr. Richard Porter, Chief Business and Scientific Officer of uniQure and founder and CEO of Corlieve Therapeutics, has more than 25 years of R&D experience. Previously, he served as COO of Therachon until its acquisition by Pfizer and Global Head of Scientific Business Strategy and Operations for Neuroscience Ophthalmology and Rare Disease at Roche.

Richard earned his Ph.D. in neuropharmacology from Southampton University and conducted his postdoctoral training at Strong Memorial Hospital and the University of Oxford.